Albany, NY -- (SBWIRE) -- 08/01/2017 -- The global market for combination drugs diagnostics is witnessing exponential growth, thanks to the higher efficiency associated with the combination diagnosis and the accelerated approval of drugs by the regulatory bodies. Researchers anticipate the scenario to remain same over the next few years, since, as states by the WHO, around 141% of the overall global population is expected to suffer from neurological disorders by 2020.

To address the increasing needs of patients across the world, combination drugs are being introduced in the market. Some of the popular combination drugs available in the global market are Atripla, Kaletra, Combivir, Trizivir, Truvada, Excalia, Contrave, Symbax, Symbicort, Flutiform, Advair/Seretide, Janumet, Berodual, Duovent, Augmentin, Primaxin, Bacterin, and Zosyn.

This in-depth research report on the global market for combination drugs diagnostics offers a thorough analysis, focusing especially on the past and current performance of this market. The market's growth prospects has also been examined exhaustively in this research study to predict its future status.

This report gives readers a comprehensive overview of the Combination Drugs Diagnostics Market:

The global market for combination drugs diagnostics is projected to gain significantly from the substantial rise in the global geriatric population base, technologically enhanced diagnostic procedures, and the increasing investments in the research and development operations in the years to come. However, the high manufacturing costs and the risks associated with the side effects may create hindrance to the growth of this market over the next few years.

Antimicrobial catheters have surfaced as the most valued product in this market and, thanks to the rising awareness about antimicrobial agents among consumers, cost efficient treatment, and the reduction in the incidence rate of infections, this scenario is likely to remain so over the forthcoming years.

In terms of geography, the global market for combination drugs diagnostics has its presence across the Middle East and Africa, Asia Pacific, North America, Latin America, and Europe. Among these, North America has occupied the dominant position and is anticipated to remain seated here over the next few years, thanks to the extensive research and development activities and the presence of a large pool of market players.

Apart from this, the rising awareness among consumers pertaining to diabetes and cardiovascular diseases and various government initiatives to curb the prevalence of these disorders is also anticipated to accentuate the demand for combination drugs in this region in the near future, leading to a substantial market growth.

While Europe has acquired the second position in this market, it is Asia Pacific, which is likely to demonstrate a high-paced rise over the forthcoming years, thanks to the robust economic growth and the improvement in the medical and healthcare infrastructure, advancements in healthcare facilities, and expansion in product portfolio in several Asian countries, such as India, Japan, China, and Malaysia.